A comparison of metronidazole and single-dose ornidazole for the treatment of dientamoebiasis  by Kurt, Ö. et al.
ORIGINAL ARTICLE 10.1111/j.1469-0691.2008.02002.x
A comparison of metronidazole and single-dose ornidazole for the
treatment of dientamoebiasis
O¨. Kurt, N. Girginkardes¸ler, I. C. Balciog˘lu, A. O¨zbilgin and U¨. Z. Ok
Department of Parasitology, School of Medicine, Celal Bayar University, Manisa, Turkey
ABSTRACT
Recent reports of the pathogenic potential of Dientamoeba fragilis have underlined the need for an
effective treatment against this colon-dwelling protozoan. Metronidazole is a well-known and
commonly used anti-protozoal agent, but another 5-nitroimidazole derivative, ornidazole, may be
preferable, where available, because of its longer half-life and fewer side-effects. This study compared
the efficacies of metronidazole and ornidazole in a group of 112 patients with dientamoebiasis. Patients
were randomised into two treatment groups: group 1 (n = 56) received metronidazole for 5 days,
20 mg ⁄kg ⁄day for children and 1.5 g ⁄day for adults, in three oral doses, while group 2 (n = 56) received
a single oral dose of ornidazole, 30 mg ⁄ kg for children and 2 g for adults. Stool samples were examined
on the seventh and 14th days after treatment, and clinical symptoms were recorded to evaluate the
efficacy of treatment. A statistically significant difference was recorded between the efficacies of
ornidazole and metronidazole, both parasitologically (92.9% vs. 69.6%, p 0.001) and clinically (96.4% vs.
76.8%, p 0.001). Patients in the metronidazole group reported more side-effects than patients in the
ornidazole group, none of whom required termination of treatment. These results suggest that single-
dose ornidazole may be an important alternative agent for the treatment of dientamoebiasis.
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INTRODUCTION
Dientamoeba fragilis is an intestinal flagellate proto-
zoan with a worldwide distribution in both rural
and urban regions. Currently, limited information
is available concerningmany aspects of this tricho-
monad, which, following its first description in
1918,was regarded as a commensal formanyyears.
In part, this is because it is present in asymptomatic
individuals and in patients co-infected with other
pathogenic microorganisms [1]. However, numer-
ous clinical studies have now associated D. fragilis
with clinical symptoms that disappear following
the elimination of the parasite with anti-protozoal
agents [2–10].
A wide range of compounds has been used,
with varying efficacies, in the treatment of
dientamoebiasis, including metronidazole [11],
iodoquinol [12], tetracycline [13], erythromycin
[14], diphetarsone [15], paromomycin [16] and
secnidazole [2]. Chan et al. [17] used in-vitro
susceptibility tests on D. fragilis ATCC 30948 in
a dixenic culture to reveal that iodoquinol,
paromomycin and metronidazole were inhibitory
to D. fragilis, as they had limited or no activity
against the associated bacteria. However, the
absence of an axenic culture is obviously a major
obstacle in determining whether D. fragilis or the
bacterial flora was the real target of the therapeu-
tic agents [1].
5-Nitroimidazole derivatives have been used in
the treatment of various intestinal protozoal
infections for many years. Among these agents,
metronidazole is a common anti-protozoal agent
that is used worldwide, while ornidazole is a
relatively new derivative that is used in some
countries in treating particular protozoal infec-
tions, and that has higher patient compliance
because of its longer half-life [18]. The aim of the
present study was to compare the efficacies of
metronidazole and single-dose ornidazole in
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patients with dientamoebiasis. The clinical symp-
toms of the patients, as well as the side-effects of
both treatments, were recorded.
MATERIALS AND METHODS
Fresh stool samples of patients (produced within the preced-
ing 30 min) were examined for D. fragilis trophozoites in the
parasitology laboratory, on three consecutive days. The smears
prepared from these samples were immediately placed in
Schaudinn’s fixative for trichrome staining (Wheatley modifi-
cation). All samples were then examined by wet mount and
formalin ethyl acetate concentration, as described previously
[19]. Stool samples were also cultured to identify common
bacterial pathogens, e.g., Salmonella spp., Shigella spp. and
Escherichia coli. Since data from virological analyses were not
available for all individuals, these data were not included in
the study.
In total, 112 patients infected with D. fragilis who strictly
adhered to the study protocol were enrolled in the study
during a 25-month period. A questionnaire concerning clinical
symptoms before and after treatment was completed for each
patient. Diarrhoea was defined as three or more soft or liquid
stools per day for three or more days, while one formed stool a
day was considered to indicate disappearance of diarrhoea.
The patients were randomised to receive oral metronidazole
(n = 56) or ornidazole (n = 56). Metronidazole 1.5 g daily for
5 days was given in three equal doses to adults, while
20 mg ⁄kg was given to children aged 3–15 years. Ornidazole
2 g was given as a single dose to adults, and 30 mg ⁄kg was
given as a single dose to children. Metronidazole was given in
suspension form to children aged <10 years; however, because
of the unavailability of the suspension form of ornidazole in
Turkey, children aged <10 years received ground ornidazole
tablets with meals. Patients were asked not to consume other
antimicrobial agents for 1 week before and 2 weeks after both
treatment regimens. On the seventh and 14th days after the
completion of therapy, patients were invited to the laboratory
to submit fresh stool samples; these samples were examined,
using the same methods, by microscopists who were unaware
of the treatment groups.
Patients who failed to complete therapy and ⁄ or failed to
deliver at least one stool sample for the follow-up were
excluded. Patients found to be positive for D. fragilis in a
follow-up examination received repeat treatment with the
same agent and dose and were then re-evaluated. Liver
function tests were performed for patients who were still
infected with D. fragilis after the second dose; unless there was
a contraindication, they then received the alternative agent
according to its treatment regimen.
Effective treatment was defined as eradication of D. fragilis
and resolution of the clinical symptoms in patients after the
first treatment regimen. Disappearance of D. fragilis in follow-
up stool examinations was considered to be a parasitological
cure, while the absence of clinical symptoms, as reported by
the patient, at the second follow-up examination was consid-
ered to be a clinical cure. Initial informed consent was obtained
from adult patients or from the parents of children. The study
was carried out in accordance with the Helsinki Declaration
and was approved by the Ethics Committee of the School
of Medicine, Celal Bayar University (Registration number:
2003-49).
The efficacies of the two drugs were compared by
chi-squared tests (with Yates’ correction) and Fisher’s exact test.
RESULTS
The patients were aged between 3 and 84 years
(mean 41.6 ± 18.5 years for ornidazole and
35.5 ± 23.9 years for metronidazole; p 0.07), with
25 (22.3%) patients being aged <15 years. The
patients were randomised into two treatment
groups, with no significant difference in terms
of gender (p 0.36). No bacterial pathogens were
isolated from the stool samples of patients with
D. fragilis infection. In both treatment groups,
D. fragilis was the only pathogen in 60 (53.6%)
cases, accompanied by the following protozoa:
Blastocystis hominis (41 cases, 36.6%), Entamoeba
histolytica ⁄ dispar (seven cases, 6.3%), Giardia
lamblia (three cases, 2.7%), and Entamoeba coli
and Endolimax nana (one case, 0.9%). The most
frequent clinical symptoms were fatigue (67.9%),
flatulence (58.9%), abdominal pain (53.6%) and
diarrhoea (33.9%).
Parasitological and clinical cures after the first
regimen were achieved in 52 (92.9%) and 54
(96.4%) patients, respectively, in the ornidazole
group, and in 39 (69.6%) and 43 (76.8%) patients,
respectively, in the metronidazole group
(Table 1). Eradication of D. fragilis following the
second regimen was confirmed in all four remain-
ing patients in the ornidazole group, and in eight
of the 17 remaining patients in the metronidazole
group. Serum levels of alanine aminotransferase
and aspartate transaminase were within the
normal range in the remaining nine patients,
who were then treated successfully with a single
2-g dose of ornidazole.
Table 2 compares the efficacies of both treat-
ment regimens according to the presence or
absence of other intestinal protozoa. In terms of
both parasitological and clinical cures, ornidazole
was more effective than metronidazole, regard-
less of whether other intestinal protozoa were also
present.
Table 1. Comparison of the efficacies of metronidazole
and ornidazole after the first treatment regimen
Agent
Treatment success
n (%)
Treatment failure
n (%)
Total
n (%) pParasitological Clinical Parasitological Clinical
Ornidazole 52 (92.9) 54 (96.4) 4 (7.1) 2 (3.6) 56 (100) 0.001
Metronidazole 39 (69.6) 43 (76.8) 17 (30.4) 13 (23.2) 56 (100)
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Few patients reported side-effects (Table 3),
and none of these side-effects was sufficiently
severe to warrant termination of treatment.
Parents of the children in both groups reported
no difficulty in delivering the agents to their
children.
DISCUSSION
There is currently no consensus concerning the
definitive treatment of dientamoebiasis, and all
current therapeutic regimens used for D. fragilis
are considered to be investigational by the US
Food and Drug Administration [1]. No large-scale
randomised trials of dientamoebiasis treatment
have been reported previously. Iodoquinol and
tetracycline are the most commonly used agents
for the treatment of D. fragilis infection [1].
Iodoquinol (diiodohydroxyquin) has been found
to be particularly effective in North America [4].
Paromomycin is regarded as second-line therapy
[11], with clinical and parasitological cure rates of
87% and 80%, respectively, being reported in the
treatment of 15 Dientamoeba-infected children [16].
5-Nitroimidazoles are currently used in
the treatment of protozoal infections such as
amoebiasis, giardiasis and trichomoniasis. Metro-
nidazole has well-known efficacy against intesti-
nal protozoa and anaerobic bacteria. Ornidazole is
a relatively new derivative with a 1.7-fold longer
half-life than metronidazole, thus enabling its use
as a single dose and promoting patient compli-
ance with treatment, which is particularly crucial
among children and the elderly [20]. As iodoqu-
inol and paromomycin are currently unavailable
in Turkey, and tetracycline, despite being effec-
tive, has limited use because of its deleterious
effects on dental development in children [1],
metronidazole is the first choice for treating
D. fragilis infections. The efficacy of metronida-
zole was reported to be only moderate in Swedish
patients with dientamoebiasis [21], but treatment
with metronidazole 500–750 mg in three equal
doses a day for 5–7 days has been reported to
be effective in children with dientamoebiasis
[11,22], and Preiss et al. [14] treated 70% of
D. fragilis-infected children with metronidazole.
Secnidazole, another long-acting derivative of the
5-nitroimidazoles, produced clinical and parasi-
tological cures in 27 and 34, respectively, of 35
children with dientamoebiasis [2].
In the present study, the parasitological and
clinical efficacies of ornidazole (92.9% and
96.4%, respectively) were significantly higher
after the initial regimen (p 0.001) than those of
metronidazole (69.3% and 76.8%, respectively).
The efficacy of ornidazole was also superior to
that of metronidazole, regardless of whether
other intestinal protozoa were present, including
B. hominis (90.0% vs. 71.4%), which is fre-
quently detected with D. fragilis in symptomatic
patients [7,10]. Diarrhoea was resolved in all
patients, while the frequencies of abdominal pain
Table 2. Efficacies of ornidazole
and metronidazole according to the
presence or absence of other intesti-
nal protozoa
Agent Accompanying intestinal protoza
Result
Treatment success (%) Treatment failure (%) Total (%)
Ornidazole None (Dientamoeba fragilis alone) 30 (100) – 30 (100)
Blastocystis hominisa 18 (90) 2 (10) 20 (100)
Giardia lamblia 1 (50) 1 (50) 2 (100)
Entamoeba histolytica ⁄ dispar 3 (75) 1 (25) 4 (100)
Total 52 (92.9) 4 (7.1) 56 (100)
Metronidazole None (D. fragilis alone) 19 (63.3) 11 (36.7) 30 (100)
B. hominisa 15 (71.4) 6 (28.6) 21 (100)
G. lamblia 1 (100) – 1 (100)
E. histolytica ⁄ dispar 3 (100) – 3 (100)
Entamoeba coli and Endolimax nana 1 (100) – 1 (100)
Total 39 (69.6) 17 (30.4) 56 (100)
aSamples having ‡5 B. hominis cells under ·400 magnification.
Table 3. Side-effects of metronidazole and ornidazole
according to the reports of patientsa
Side-effect
Metronidazole
(n = 56)
Ornidazole
(n = 56)
n % n %
Nausea 4 7.1 3 5.4
Vomiting 2 3.6 – –
Anorexia 2 3.6 – –
Headache – – 1 1.8
Dizziness 1 1.8 2 3.6
Dry mouth 4 7.1 – –
Metallic taste 3 5.4 – –
Insomnia 1 1.8 – –
Vertigo 1 1.8 – –
aSome patients reported more than one side-effect.
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(53.6%) and flatulence (58.9%) declined to 1.1%
and 3.4%, respectively, after therapy. Probably
because of its possible multifactorial origin, the
frequency of fatigue also declined from 67.9%
to 14.6% after treatment.
Agents used for the treatment of dientamoebi-
asis have been associated with several side-
effects. Diphetarsone has been associated with
transient liver function abnormalities [15], while
tetracycline is contraindicated in children because
of its deleterious effects on dental development
[1]. However, a recent study reported no side-
effects following the use of paromomycin in
paediatric patients [16]. A few side-effects were
reported in the present study, but none was
sufficiently severe to require the termination of
treatment. Nausea was the most frequent side-
effect in both groups (7.1% and 5.4% in the
metronidazole and ornidazole groups, respec-
tively), and some patients in the metronidazole
group also complained of a dry mouth (7.1%) and
a metallic taste (5.4%).
To our knowledge, this is the first time that
ornidazole has been used for the treatment of
patients with dientamoebiasis. A single dose of
ornidazole was revealed to be effective and well-
tolerated, with high compliance in all age groups.
Co-infection with B. hominis had no significant
effect on outcome. Thus, ornidazole may be
regarded as a novel drug of choice for the
treatment of D. fragilis infection.
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